Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Dutcher · SciRah

Researcher profile · Semantic Scholar

J. Dutcher

Share profile

J. Dutcher — researcher profile on SciRah

h-index: 67
Works: 331
Citations: 24K

Most-cited papers

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
B. Rini, S. Halabi, J. Rosenberg, W. Stadler +7 more
2010Journal of Clinical Oncology777 citations Open access
Semantic Scholar
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
N. Haas, J. Manola, R. Uzzo, K. Flaherty +21 more
2016The Lancet577 citations Open access
Semantic Scholar
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
W. Stadler, R. Figlin, David F. McDermott, J. Dutcher +16 more
2010Cancer253 citations
Semantic Scholar
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
J. Dutcher, D. Schwartzentruber, H. Kaufman, S. Agarwala +3 more
2014Journal of Immunotherapy for Cancer225 citations Open access
Semantic Scholar
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer
N. Haas, J. Manola, J. Dutcher, K. Flaherty +4 more
2017JAMA Oncology154 citations Open access
Semantic Scholar
The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma
D. McDermott, Su-Chun Cheng, S. Signoretti, K. Margolin +23 more
2014Clinical Cancer Research144 citations Open access
Semantic Scholar
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
E. Buchbinder, J. Dutcher, G. Daniels, B. Curti +11 more
2019Journal of Immunotherapy for Cancer141 citations Open access
Semantic Scholar
Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
B. Rini, M. Garrett, B. Poland, J. Dutcher +7 more
2013Journal of clinical pharmacology137 citations Open access
Semantic Scholar
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.
A. Correa, Opeyemi A. Jegede, N. Haas, K. Flaherty +10 more
2019Journal of Clinical Oncology130 citations Open access
Semantic Scholar
Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
J. Maroto, G. Hudes, J. Dutcher, T. Logan +6 more
2011Journal of Clinical Oncology109 citations
Semantic Scholar
Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors.
G. Malouf, P. Camparo, V. Molinie, G. Dedet +10 more
2011Journal of Urology99 citations
Semantic Scholar
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
A. Alva, G. Daniels, M. Wong, H. Kaufman +17 more
2016Cancer Immunology and Immunotherapy98 citations Open access
Semantic Scholar
The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC).
D. McDermott, M. Ghebremichael, S. Signoretti, K. Margolin +6 more
201094 citations
Semantic Scholar
Recent developments in the treatment of renal cell carcinoma
J. Dutcher
2013Therapeutic Advances in Urology85 citations Open access
Semantic Scholar
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma
A. Correa, Opeyemi A. Jegede, N. Haas, K. Flaherty +11 more
2021European Urology71 citations Open access
Semantic Scholar
Targeted therapies and the treatment of non-clear cell renal cell carcinoma.
J. Bellmunt, J. Dutcher
2013Annals of Oncology60 citations Open access
Semantic Scholar
Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy
J. Dutcher, D. Nanus
2011Medical Oncology58 citations
Semantic Scholar
On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment-Cytokines, Targeted Therapy, and Immunotherapy.
J. Dutcher, R. Flippot, Jaleh Fallah, B. Escudier
2020American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting53 citations Open access
Semantic Scholar
Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
G. Procopio, J. Bellmunt, J. Dutcher, S. Bracarda +5 more
2013British Journal of Cancer52 citations Open access
Semantic Scholar
Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.
N. Haas, J. Manola, R. Uzzo, M. Atkins +11 more
201549 citations
Semantic Scholar
Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
L. Appleman, M. Puligandla, S. Pal, W. Harris +12 more
2019Journal of Clinical Oncology45 citations
Semantic Scholar
Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program
R. Bukowski, W. Stadler, D. McDermott, J. Dutcher +15 more
2010Oncology45 citations
Semantic Scholar
Plasma KIM-1 is associated with recurrence risk after nephrectomy for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)
Wenxin Xu, M. Puligandla, Brian Halbert, N. Haas +6 more
2021Clinical Cancer Research44 citations Open access
Semantic Scholar
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
E. Buchbinder, Anasuya Gunturi, Jessica C. Perritt, J. Dutcher +16 more
2016Journal of Immunotherapy for Cancer43 citations Open access
Semantic Scholar
Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).
T. Choueiri, S. Pal, D. McDermott, D. Ramies +5 more
2012Journal of Clinical Oncology38 citations
Semantic Scholar
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry
B. Curti, G. Daniels, D. McDermott, J. Clark +9 more
2017Journal of Immunotherapy for Cancer37 citations Open access
Semantic Scholar
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM
J. Clark, M. Wong, H. Kaufman, G. Daniels +30 more
2016Clinical Genitourinary Cancer34 citations Open access
Semantic Scholar
The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).
D. McDermott, J. Manola, M. Pins, K. Flaherty +5 more
2013Journal of Clinical Oncology34 citations
Semantic Scholar
Thomas F. Gajewski and F. Stephen Hodi (eds): Targeted therapeutics in melanoma. Current clinical oncology, Series edited by Maurie Markman
J. Dutcher
2013Medical Oncology30 citations
Semantic Scholar
A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: A Cytokine Working Group (CWG) Study
U. Dandamudi, M. Ghebremichael, J. Sosman, J. Clark +12 more
2013Journal of immunotherapy27 citations
Semantic Scholar
Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).
A. Nixon, S. Halabi, Ivo D. Shterev, Mark D. Starr +8 more
201325 citations
Semantic Scholar
ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features.
N. Haas, J. Manola, M. Pins, Glenn Liu +5 more
2016Journal of Clinical Oncology22 citations
Semantic Scholar
Effect of renal impairment on the pharmacokinetics and safety of axitinib
Ying Chen, B. Rini, R. Motzer, J. Dutcher +6 more
2015Targeted oncology21 citations Open access
Semantic Scholar
State-of-the-Art Management of Renal Cell Carcinoma
W. Mourad, J. Dutcher, R. Ennis
2014American Journal of Clinical Oncology20 citations
Semantic Scholar
Integrating innovative therapeutic strategies into the management of renal cell carcinoma.
J. Dutcher, W. Mourad, R. Ennis
2012Oncology20 citations
Semantic Scholar
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
J. Clark, B. Curti, Elizabeth J. Davis, H. Kaufman +10 more
2021Journal of Investigative Medicine18 citations Open access
Semantic Scholar
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
C. Ager, M. Reilley, C. Nicholas, Todd Bartkowiak +496 more
2016Journal for ImmunoTherapy of Cancer18 citations Open access
Semantic Scholar
Association of Age and Sex with Mortality Following Adjuvant Therapy for Renal Cancer
R. Mamtani, X. V. Wang, B. Gyawali, R. DiPaola +3 more
2019Cancer17 citations Open access
Semantic Scholar
Update on the biology and management of renal cell carcinoma
J. Dutcher
2018Journal of Investigative Medicine15 citations Open access
Semantic Scholar
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma
A. Molina, J. C. van der Mijn, P. Christos, J. Wright +5 more
2020Investigational new drugs14 citations
Semantic Scholar
Angiogenic factor and cytokine analysis among patients treated with adjuvant VEGFR TKIs in resected renal cell carcinoma
Wenxin Xu, M. Puligandla, J. Manola, A. Bullock +9 more
2019Clinical Cancer Research14 citations Open access
Semantic Scholar
Experience with sorafenib and the elderly patient
J. Dutcher, N. Tannir, J. Bellmunt, B. Escudier
2010Medical Oncology14 citations
Semantic Scholar
Novel Management of Pruritus in Patients Treated With IL-2 for Metastatic Renal Cell Carcinoma and Malignant Melanoma
S. Lee, M. Baig, V. Rusciano, J. Dutcher
2010Journal of immunotherapy14 citations
Semantic Scholar
A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group Study (CWGS).
U. Dandamudi, M. Ghebremichael, J. Sosman, M. Regan +6 more
201014 citations
Semantic Scholar
Atrasentan in Patients with Advanced Renal Cell Carcinoma: A Phase II Trial of the ECOG-ACRIN Cancer Research Group (E6800)
M. Carducci, J. Manola, S. Nair, Glenn Liu +3 more
2015Clinical Genitourinary Cancer10 citations Open access
Semantic Scholar
Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies.
A. Bailey, Su-Chun Cheng, E. Kwon, B. Leibovich +14 more
201310 citations
Semantic Scholar
ECOG 1808: Randomized phase II trial of sunitinib with or without gemcitabine in advanced kidney cancer with sarcomatoid features.
N. Haas, M. Puligandla, D. McDermott, J. Dutcher +10 more
20169 citations
Semantic Scholar
Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).
T. Choueiri, S. Pal, D. McDermott, D. Ramies +5 more
2012Journal of Clinical Oncology9 citations
Semantic Scholar
Antitumor activity observed in a phase I drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC).
T. Choueiri, S. Pal, M. Cabanillas, D. Ramies +4 more
2011Journal of Clinical Oncology9 citations
Semantic Scholar
Classic case of unicentric mixed-type Castleman's disease.
R. Nagubandi, Yanhua Wang, J. Dutcher, Prakashchandra M. Rao
2013Journal of Clinical Oncology8 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. McDermott×16
Invite
D. McDermott — researcher profile on SciRah
B. Curti×13
Invite
B. Curti — researcher profile on SciRah
M. Atkins×11
Invite
M. Atkins — researcher profile on SciRah
R. DiPaola×11
Invite
R. DiPaola — researcher profile on SciRah

×10

Invite

N. Haas — researcher profile on SciRah

Invite

J. Manola — researcher profile on SciRah

Invite

J. Clark — researcher profile on SciRah

Invite

K. Flaherty — researcher profile on SciRah

Invite

M. Pins — researcher profile on SciRah

Invite

M. Ernstoff — researcher profile on SciRah

Invite

R. Uzzo — researcher profile on SciRah

Invite

T. Logan — researcher profile on SciRah